ClinicalTrials.gg
CompletedNCT05017480Updated May 1, 2024Results posted

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

A Phase 2 interventional study of CBP-201 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Connect Biopharm LLC. Completed at 48 sites in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-01.

Sponsored by Connect Biopharm LLC · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 206 studies in Dermatitis, Atopic with a site in China — 64 open to participants now, 82 under way, 29 of them phase 3. Dermatitis, Atopic · China.

Enrollment
52nd of 190
330 · median 164
Started
2021
with 12 others
Phase 2
58 of 206
16 open now
Registered
34th of 206
by date

Among the 206 studies in Dermatitis, Atopic with a site in China, this one is the 52nd largest by enrollment of the 190 interventional ones that give a count, is one of 13 that started in 2021, is one of 58 in phase 2, and was the 34th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

64 of the 206 studies in Dermatitis, Atopic with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 206 studies in Dermatitis, Atopic with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.

Read the detailed description

This study is a randomized, double-blind, multi-center, controlled study designed to assess the efficacy, safety and PK characteristics of CBP-201 in eligible subjects with moderate to severe AD.

The study includes a screening period, a treatment period and a follow-up period. The treatment period is divided into two stages.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 12≤ age ≤75 years at the screening visit, male or female;
  2. Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014[1]) at the screening, visit and:

    a) The subject has been suffering from the disease for more than 1 year at the time of screening, and according to the judgment of the investigator, the subject has had poor response to topical drugs such as , phosphodiesterase-4 (PDE-4) inhibitors or calcineurin inhibitors (TCI), or it is not medically suitable for the subject to receive topical drug treatment (e.g., there are important side effects or safety risks);

    Note: Poor response is defined as any of the following conditions:

    i. The patient has not achieved and maintained response or reached a low disease activity state (equivalent to IGA 0=asymptomatic to 2=mild) despite regular use of topical therapy during the 1 year before baseline; ii. The patient has received systemic treatment for AD despite regular use of topical therapy during the 1 year before baseline.

    b. At the screening and baseline visit, Investigator's Global Assessment (IGA) score ≥3 (according to the validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD™] scale, see Section 17.4 Appendix D), Eczema Area and Severity Index (EASI) score≥16 (see Section 17.5, Appendix E), and≥10% body surface area (BSA) of AD involvement(see Section 17.6, Appendix F); c. The average score of the maximum pruritus intensity in the Peak Pruritus Numerical Rating Scale (PP-NRS) ≥4 (see Section 17.1, Appendix A).

    Note: The baseline average score of maximum pruritus intensity in the PP-NRS will be calculated based on the average value of the maximum pruritus intensity in the PP-NRS score [daily score range 0-10] every day within 7 days before randomization. In these 7 days, the scores of at least 4 days are required for the calculation of the baseline average score. If the patient's reporting days are less than 4 days in the 7 days before the planned date of randomization, randomization should be postponed until the requirements are met, but it is not allowed to exceed the maximum screening period of 28 days.

  3. Able and willing to use a stable dose of a mild emollient at the AD involvement area twice a day starting from at least 7 days before baseline and continue to use it during the study period (see Section 8.1.1.2 Emollients).
  4. Female subjects of (FCBP) and male subjects who have not undergone vasectomy must take highly effective measures during the entire study period, including the 8-week follow-up period after discontinuation of study drug. women (determined by testing follicle stimulating hormone [FSH]) and women with a record of surgical sterilization (i.e., tubal ligation or hysterectomy or bilateral oophorectomy) before the screening visit can be considered infertile.

    Highly effective contraceptive measures include:

    i. Abstinence (acceptable only if it is part of the subject's routine lifestyle); ii. Hormones (oral, patch, ring, injection, implant) combined with male condoms. This measure must be used at least 30 days before the first study drug administration. Otherwise, another acceptable method of contraception must be used; iii. Intrauterine device (IUD) combined with male condoms; iv. Exceptions are: a) women who have had amenorrhea for at least 12 consecutive months without using drugs known to cause amenorrhea, and have a recorded FSH level greater than 40 mIU/mL or in the postmenopausal range; or b) surgical sterilization (e.g., hysterectomy, bilateral oophorectomy).

  5. Subjects and/or their guardians have the ability to learn the study requirements and process, and voluntarily take part in the clinical trial and sign an form (ICF); note: for subjects ≥18 years: subjects voluntarily agree to take part in the study by themselves and sign ICF; for subjects aged 12-17 years: subjects and their guardians voluntarily agree to take part in the study, the guardians sign the ICF, and the subjects sign the informed assent form for minors by themselves.
  6. Subjects and/or their guardians are willing and able to comply with study visits and related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received any of the following treatments:

    1. Treatment with dupilumab or any anti-IL-4Rα or IL-13 antibodies;
    2. Topical drugs for treatment of AD or have the potential to affect the assessment of AD, including but not limited to , PDE-4 inhibitors, Janus kinase (JAK) inhibitors, aromatic hydrocarbon receptor agonists, tacrolimus or pimecrolimus, or traditional Chinese medicine (TCM) or herbal medicine, etc. within 2 weeks before baseline;
    3. Have undergone bleaching baths ≥ twice within 2 weeks before baseline;
    4. Have begun to use prescription emollients or emollients containing additives (e.g., ceramide, hyaluronic acid, urea, or filaggrin breakdown products) to treat AD from the screening period (if the subject has started using this kind of emollient before the screening visit, they can continue to use it at a stable dose; if the subject is intolerable to the emollients provided uniformly by the sponsor during the screeing period, he/she can change to emollient of this kind used previously, but it must be used at a stable dose for at least 7 days before baseline and during the study period);
    5. Treatment with systemic corticosteroids or other /immunomodulating substances (e.g., cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, or oral JAK inhibitors) due to AD or other diseases within 4 weeks before baseline (except for corticosteroid inhalers and nasal sprays);
    6. Treatment with systemic TCM or herbal treatment within 4 weeks before baseline (note: except for those for the treatment of diseases other than AD, which are necessary and will neither increase the risks of the subjects nor affect the assessment of the study in accordance with the medical judgements of the investigator and/or specialist physician);
    7. Treatment with phototherapy (narrow band ultraviolet B [NBUVB], ultraviolet B [UVB], ultraviolet A1 [UVA1], psoralen + ultraviolet A [PUVA]), sunbed or any other light emitting device (LED) therapy within 4 weeks before baseline;
    8. Have used any drug/treatment within 4 weeks before baseline or 5 drug half-lives, whichever is longer;
    9. Treatment with other biological agents (e.g., omalizumab) within 3 months before baseline or 5 drug half-lives (if known), whichever is longer;
    10. Have been vaccinated with live (attenuated) vaccine within 8 weeks before baseline;
    11. Treatment with cell depletion agents (e.g., rituximab) within 6 months before baseline;
    12. Treatment with allergen specific immunotherapy (SIT) within 6 months before baseline (except those who were already on stable-dose therapy before baseline).

    Eligibility criteria Inclusion criteria

    Patients must meet all of the following criterias to be enrolled into this study:

  2. Patients who meet any of the following:

    1. History of to L-histidine, trehalose or Tween 80;
    2. Other skin complications in addition to AD that may interfere with the study assessments;
    3. Any history of vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC);
    4. History of malignant tumor within 5 years before screening, except for cervical carcinoma in situ or non- cutaneous squamous cell carcinoma or basal cell carcinoma;
    5. Active tuberculosis (TB) at the screening visit, latent tuberculosis or a history of non-tuberculous Mycobacterium infection

    Note:

    • Unless there is a clear specialist record proving that the patient has received adequate treatment and is currently able to start receiving biological treatment (based on the medical judgment of the investigator and/or infectious disease specialist);
    • If necessary, T-spot test may be used for auxiliary diagnosis of suspected tuberculosis patients; f. Positive for surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for antibody and HCV RNA polymerase chain reaction; or serologically positive for (HIV) at the screening visit; g. Any of the following laboratory test abnormalities at the screening visit: i. or alanine aminotransferase > 2 times the (ULN), or total > 1.5×ULN ii. Serum creatinine > 1.2×ULN iii. \< 8.5 g/dl (85.0 g/L) in male patients and \< 8.0 g/dl (80.0 g/L) in female patients iv. White blood cell count \<3.0×109/L or ≥14×109/L v. count \<100×109/L h. Planning to undergo major surgical operations during the study period; i. Used systemic treatment with antibiotics, antiviral drugs, antiparasitic drugs, antigenic drugs, or antifungal drugs due to infection within 4 weeks before the baseline visit, or suffered from superficial skin infection (e.g., impetigo) within 2 weeks before baseline (after the infection subsides, the subjects can be rescreened); j. History of parasite infection (e.g., helminth) within 6 months before baseline; k. According to the investigator's judgment, there is a known or suspected history of immunosuppression within 6 months before baseline, including a history of invasive opportunistic infections, such as aspergillosis, coccidiosis, histoplasmosis, HIV, listeriosis, Pneumocystis or tuberculosis, even if the infection has subsided; or there is an abnormally frequently recurrent or persistent infection; l. History of alcohol or drug abuse within 2 years before the screening visit; m. Any other medical or psychological condition (including laboratory test abnormalities, parameters, etc.) at the screening visit, which, as judged by the investigator, may indicate new and/or insufficiently understood diseases, may put the patient at an unreasonable risk due to his/her participation in the clinical trial, may lead to unreliable results of the patient's participation, or may interfere with the study assessments. The specific reasons for patients excluded due to this criterion will be indicated in the study documents (medical records, eCRF, etc.).
  3. Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    CBP-201 Dose

    CBP-201 Dose subcutaneous (SC) injection

    Drug: CBP-201

  • Placebo comparator
    Placebo

    subcutaneous (SC) injection

    Drug: Placebo

Interventions

  • CBP-201 subcutaneous(SC) injection.

  • DrugPlacebo

    subcutaneous(SC) injection

06

What researchers measure

Primary outcomes

  1. Investigator Global Assessment (IGA) (0-1)

    The percentage of subjects whose IGA score is 0-1 and decreased by ≥2 points The Validated Investigator Global Assessment for AD (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).

    Time frame: Baseline to Week16

Secondary outcomes

  1. Eczema Area and Severity Index (EASI)-75

    The percentage of subjects achieving EASI-75 (EASI score is decreased by ≥75% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).

    Time frame: Baseline to Week16

  2. Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 4 Points)

    The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 4 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

    Time frame: Baseline to Week16

  3. Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 3 Points)

    The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 3 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

    Time frame: Baseline to Week16

  4. Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)

    Change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

    Time frame: Baseline to Week16

  5. Eczema Area and Severity Index (EASI)-90

    The percentage of subjects achieving EASI-90 (EASI score is decreased by ≥90% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).

    Time frame: Baseline to Week16

  6. Percentage Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)

    Percentage change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

    Time frame: Baseline to Week16

07

Results

Posted May 1, 2024

Participant flow

Stage 1 Study
Participant flow — Stage 1 Study
MilestoneGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2WGroup C: Double-blinded CBP-201 300mg Q2WGroup D: Double-blinded CBP-201 300mg Q4WGroup E: Open-Label CBP-201 300mg Q2W
Started219111000
Completed209102000
Not completed109000
Withdrew: Withdrawal by subject86000
Withdrew: Adverse event11000
Withdrew: Poor compliance11000
Withdrew: Physician decision01000
Stage 2 Study
Participant flow — Stage 2 Study
MilestoneGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2WGroup C: Double-blinded CBP-201 300mg Q2WGroup D: Double-blinded CBP-201 300mg Q4WGroup E: Open-Label CBP-201 300mg Q2W
Started0011311286
Completed001079973
Not completed0061313
Withdrew: Withdrawal by subject006911
Withdrew: Lost to follow-up00021
Withdrew: Adverse event00010
Withdrew: Covid-1900010
Withdrew: Pregnancy00001

Outcome measures

PrimaryInvestigator Global Assessment (IGA) (0-1)

The percentage of subjects whose IGA score is 0-1 and decreased by ≥2 points The Validated Investigator Global Assessment for AD (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).

Time frame:
Baseline to Week16
Reported as:
Number · percentage of participants
Investigator Global Assessment (IGA) (0-1)
percentage of participantsGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Investigator Global Assessment (IGA) (0-1)29.0 (23.0 to 35.0)5.9 (1.4 to 10.4)
SecondaryEczema Area and Severity Index (EASI)-75

The percentage of subjects achieving EASI-75 (EASI score is decreased by ≥75% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).

Time frame:
Baseline to Week16
Reported as:
Number · percentage of participants
Eczema Area and Severity Index (EASI)-75
percentage of participantsGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Eczema Area and Severity Index (EASI)-7558.6 (51.9 to 65.3)22.6 (14.5 to 30.7)
SecondaryChange in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 4 Points)

The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 4 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

Time frame:
Baseline to Week16
Reported as:
Number · percentage of participants
Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 4 Points)
percentage of participantsGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 4 Points)36.3 (29.7 to 42.8)10.5 (4.5 to 16.5)
SecondaryChange in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 3 Points)

The percentage of subjects whose weekly average PP-NRS is decreased by ≥ 3 points The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

Time frame:
Baseline to Week16
Reported as:
Number · percentage of participants
Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 3 Points)
percentage of participantsGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Change in Peak Pruritus Numerical Rating Scale(PP-NRS) (Decreased by ≥ 3 Points)50.0 (43.2 to 56.9)20.3 (12.7 to 28.0)
SecondaryChange in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)

Change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

Time frame:
Baseline to Week16
Reported as:
Least squares mean · score on a scale
Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)
score on a scaleGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)-2.95 (-3.28 to -2.62)-0.99 (-1.46 to -0.53)
SecondaryEczema Area and Severity Index (EASI)-90

The percentage of subjects achieving EASI-90 (EASI score is decreased by ≥90% from baseline) The total EASI score ranges from 0 (lowest) to 72 (highest); the higher the score, the higher the severity of AD (more severe).

Time frame:
Baseline to Week16
Reported as:
Number · percentage of participants
Eczema Area and Severity Index (EASI)-90
percentage of participantsGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Eczema Area and Severity Index (EASI)-9033.4 (27.0 to 39.8)6.4 (1.4 to 11.4)
SecondaryPercentage Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)

Percentage change in the weekly average PP-NRS The score ranges from 0 to 10, in which 0 represents "no pruritus" and 10 "worst imaginable pruritus".

Time frame:
Baseline to Week16
Reported as:
Least squares mean · percentage change of PP-NRS value
Percentage Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)
percentage change of PP-NRS valueGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2W
Percentage Change in the Weekly Average Peak Pruritus Numerical Rating Scale(PP-NRS)-40.00 (-44.80 to -35.20)-13.50 (-20.19 to -6.82)

Adverse events

Collected over Stage 1 treatment period (Day1~Week16) - Stage 2 treatment period (Week16~Week52) - Follow-up period (Week53~Week60). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group A: CBP-201 300mg Q2W0/219 (0%)1/219 (0.5%)80/219 (36.5%)
Group B: Placebo Q2W0/111 (0%)3/111 (2.7%)34/111 (30.6%)
Group C: Double-blinded CBP-201 300mg Q2W0/113 (0%)1/113 (0.9%)70/113 (61.9%)
Group D: Double-blinded CBP-201 300mg Q4W0/112 (0%)3/112 (2.7%)67/112 (59.8%)
Group E: Open-Label CBP-201 300mg Q2W0/85 (0%)6/85 (7.1%)53/85 (62.4%)
Most frequent serious events
Most frequent serious events
EventGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2WGroup C: Double-blinded CBP-201 300mg Q2WGroup D: Double-blinded CBP-201 300mg Q4WGroup E: Open-Label CBP-201 300mg Q2W
Cardiac disordersCardiac disorders0/2190/1110/1130/1122/85
Injury,poisoning and procedural complicationsInjury, poisoning and procedural complications1/2192/1110/1130/1121/85
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders1/2191/1110/1131/1121/85
Infections and infestationsInfections and infestations0/2190/1111/1130/1121/85
Endocrine disordersEndocrine disorders0/2190/1110/1130/1121/85
Eye disordersEye disorders0/2190/1110/1130/1121/85
Gastrointestinal disordersGastrointestinal disorders0/2191/1110/1131/1120/85
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders0/2190/1110/1131/1120/85
Vascular disordersVascular disorders0/2190/1111/1130/1120/85
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGroup A: CBP-201 300mg Q2WGroup B: Placebo Q2WGroup C: Double-blinded CBP-201 300mg Q2WGroup D: Double-blinded CBP-201 300mg Q4WGroup E: Open-Label CBP-201 300mg Q2W
COVID-19Infections and infestations0/2190/11138/11334/11221/85
Atopic DermatitisSkin and subcutaneous tissue disorders23/21919/11114/11327/11214/85
upper respiratory infectionInfections and infestations14/2197/11112/11312/11215/85
HyperlipidaemiaMetabolism and nutrition disorders23/2196/1113/1138/1125/85
hyperuricemiaMetabolism and nutrition disorders21/2195/1117/1133/1123/85
FeverGeneral disorders0/2190/1119/1139/1127/85
conjunctivitisInfections and infestations0/2190/1114/1133/1126/85
Tested positive for SARS-CoV-2Infections and infestations0/2190/1114/1137/1122/85
urinary tract infectionInfections and infestations0/2190/1115/1136/1125/85
Elevated alanine aminotransferaseInjury, poisoning and procedural complications0/2190/1114/1132/1125/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Mean38.6 ± 16.6539.6 ± 17.5438.9 ± 16.93
Sex: Female, Male
Sex: Female, Male(Participants)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Female7340113
Male14671217
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
American Indian or Alaska Native000
Asian219111330
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
BMI
BMI(kg/m^2)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Mean23.66 ± 3.93224.98 ± 4.82924.10 ± 4.293
Severity of Atopic Dermatitis at Baseline
Severity of Atopic Dermatitis at Baseline(Participants)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Moderate (IGA=3)9950149
Severe (IGA=4)12061181
EASI at Baseline
EASI at Baseline(units on a scale)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Mean29.27 ± 11.65828.62 ± 12.09229.05 ± 11.791
PP-NRS at Baseline
PP-NRS at Baseline(units on a scale)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Mean7.19 ± 1.6807.17 ± 1.4597.18 ± 1.607
BSA at Baseline
BSA at Baseline(units on a scale)Group A: CBP-201 300mg Q2WGroup B: Placebo Q2WTotal
Mean48.55 ± 20.66646.64 ± 21.58147.91 ± 20.965

3 further baseline measures are reported on the registry.

08

Study locations

48 sites
  • Connect Investigative Site 33
    Hefei, Anhui, China
  • Connect Investigative Site 01
    Beijing, Beijing, China
  • Connect Investigative Site 02
    Beijing, Beijing, China
  • Connect Investigative Site 03
    Beijing, Beijing, China
  • Connect Investigative Site 17
    Beijing, Beijing, China
  • Connect Investigative Site 47
    Beijing, Beijing, China
  • Connect Investigative Site 28
    Chongqing, Chongqing, China
  • Connect Investigative Site 29
    Chongqing, Chongqing, China
  • Connect Investigative Site 30
    Chongqing, Chongqing, China
  • Connect Investigative Site 36
    Chongqing, Chongqing, China
  • Connect Investigative Site 38
    Fuzhou, Fujian, China
  • Connect Investigative Site 07
    Guangzhou, Guangdong, China
  • Connect Investigative Site 25
    Guangzhou, Guangdong, China
  • Connect Investigative Site 37
    Guangzhou, Guangdong, China
  • Connect Investigative Site 46
    Guangzhou, Guangdong, China
  • Connect Investigative Site 48
    Guangzhou, Guangdong, China
  • Connect Investigative Site 43
    Shaoguan, Guangdong, China
  • Connect Investigative Site 52
    Shenzhen, Guangdong, China
  • Connect Investigative Site 41
    Haikou, Hainan, China
  • Connect Investigative Site 42
    Haikou, Hainan, China
  • Connect Investigative Site 20
    Zhengzhou, He'an, China
  • Connect Investigative Site 32
    Shijiazhuang, Hebei, China
  • Connect Investigative Site 45
    Nanyang, Henan, China
  • Connect Investigative Site 54
    Xinxiang, Henan, China
  • Connect Investigative Site 49
    Wuhan, Hubei, China
  • Connect Investigative Site 35
    Baotou, Inner Mongolia, China
  • Connect Investigative Site 26
    Nanjing, Jiangsu, China
  • Connect Investigative Site 18
    Suzhou, Jiangsu, China
  • Connect Investigative Site 55
    Wuxi, Jiangsu, China
  • Connect Investigative Site 10
    Zhenjiang, Jiangsu, China
  • Connect Investigative Site 34
    Nanchang, Jiangxi, China
  • Connect Investigative Site 44
    Yinchuan, Ningxia, China
  • Connect Investigative Site 11
    Jinan, Shandong, China
  • Connect Investigative Site 50
    Jinan, Shandong, China
  • Connect Investigative Site 51
    Jinan, Shandong, China
  • Connect Investigative Site 12
    Yantai, Shandong, China
  • Connect Investigative Site 08
    Taiyuan, Shanxi, China
  • Connect Investigative Site 24
    Taiyuan, Shanxi, China
  • Connect Investigative Site 39
    Yuncheng, Shanxi, China
  • Connect Investigative Site 05
    Tianjin, Tianjin, China
  • Connect Investigative Site 06
    Tianjin, Tianjin, China
  • Connect Investigative Site 13
    Shanxi, Xi'an, China
  • Connect Investigative Site 22
    Ürümqi, Xinjiang, China
  • Connect Investigative Site 53
    Qujing, Yunnan, China
  • Connect Investigative Site 14
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 15
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 16
    Hangzhou, Zhejiang, China
  • Connect Investigative Site 19
    Jinhua, Zhejiang, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Dec 2022, 15 months.

Results were first posted in May 2024, 1 year 5 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 15 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2021
First posted
Aug 23, 2021
StartActual
Aug 31, 2021
Primary completionActual
Dec 1, 2022
CompletionActual
Sep 28, 2023
Results first posted
May 1, 2024
Last update
May 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05017480
Lead sponsor
Connect Biopharm LLC
Responsible party
Sponsor
First posted
Aug 23, 2021
Start date
Aug 31, 2021
Primary completion
Dec 1, 2022
Completion
Sep 28, 2023
Results posted
May 1, 2024
Last update
May 1, 2024

Study contacts

Suzhou Connect
study director · Connect Biopharm LLC

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-201

Start the discussion